Advertisement

Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma

  • Ai MuroiEmail author
  • Masashi Mizumoto
  • Eiichi Ishikawa
  • Satoshi Ihara
  • Hiroko Fukushima
  • Takao Tsurubuchi
  • Hideyuki Sakurai
  • Akira Matsumura
Original Article

Abstract

Introduction

Diffuse intrinsic pontine glioma (DIPG) is a type of brain malignancy with a very poor prognosis. Although various radiation and chemotherapy protocols have been attempted, only conventional radiotherapy has yielded improvements in survival. In this study, we aimed to compare proton therapy versus conventional photon radiotherapy in terms of the outcomes of pediatric patients with DIPG.

Methods

This retrospective review included 12 pediatric patients with newly diagnosed DIPG who received a total proton therapy dose of 54 Gy (relative biological effectiveness) in 30 fractions at the University of Tsukuba Hospital between 2011 and 2017 (proton group). We additionally reviewed the medical records of 10 patients with DIPG who previously underwent conventional photon radiotherapy at our institute (historical cohort).

Results

The median progression-free survival (PFS) duration was 5 months (range 1–11 months), and the 6-, 12-, and 18-month PFS rates were 50%, 33%, and 25%, respectively. The median overall survival (OS) duration was 9 months (range 4–48 months), and the 6-, 12-, 18-, and 24-month OS rates were 66.8%, 50%, 41%, and 20%, respectively. There were no significant differences in survival between the proton and historical groups (PFS, p = 0.169 and OS, p = 0.16).

Conclusions

Proton therapy was well tolerated by the majority of patients. No severe adverse events, including radiation necrosis, were recorded. Proton therapy did not yield superior survival outcomes vs. conventional photon radiotherapy in patients with DIPG at our institution. Further research is needed to identify the factors associated with better survival in this population.

Keywords

Proton therapy Diffuse intrinsic pontine glioma Radiotherapy Reirradiation 

Notes

Acknowledgments

We would like to thank Editage (www.editage.com) for the English language editing.

Author contributions

All authors contributed to the study conception and design. Material preparation and data collection were performed by AM, MM, TT, HF, and SI. The first draft of the manuscript was written by AM, MM, and EI and all authors commented on previous versions of the manuscript. HS, and AMa critically supervised the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Ethics Committee of the University of Tsukuba Hospital.

References

  1. 1.
    Nakata K, Ito Y, Magadi W, Bonaventure A, Stiller CA, Katanoda K, Matsuda T, Miyashiro I, Pritchard-Jones K, Rachet B (2017) Childhood cancer incidence and survival in Japan and England: a population-based study (1993-2010). Cancer Sci 109:422–434.  https://doi.org/10.1111/cas.13457 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248.  https://doi.org/10.1016/S1470-2045(06)70615-5 CrossRefPubMedGoogle Scholar
  3. 3.
    Mizumoto M, Oshiro Y, Yamamoto T et al (2017) Proton beam therapy for pediatric brain tumor. Neurol Med Chir (Tokyo) 57:343–355.  https://doi.org/10.2176/nmc.ra.2017-0003 CrossRefGoogle Scholar
  4. 4.
    Allen J, Siffert J, Donahue B et al (1999) A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86:1064–1069CrossRefGoogle Scholar
  5. 5.
    Mandell LR, Kadota R, Freeman C et al (1999) There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43:959–964CrossRefGoogle Scholar
  6. 6.
    Jennings MT, Sposto R, Boyett JM et al (2002) Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children’s Cancer Group. J Clin Oncol 20:3431–3437.  https://doi.org/10.1200/JCO.2002.04.109 CrossRefPubMedGoogle Scholar
  7. 7.
    Janssens GO, Jansen MH, Lauwers SJ et al (2013) Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys 85:315–320.  https://doi.org/10.1016/j.ijrobp.2012.04.006 CrossRefPubMedGoogle Scholar
  8. 8.
    Zaghloul MS, Eldebawy E, Ahmed S, Mousa AG, Amin A, Refaat A, Zaky I, Elkhateeb N, Sabry M (2014) Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol 111:35–40.  https://doi.org/10.1016/j.radonc.2014.01.013 CrossRefPubMedGoogle Scholar
  9. 9.
    Frappaz D, Schell M, Thiesse P, Marec-Bérard P, Mottolese C, Perol D, Bergeron C, Philip T, Ricci AC, Galand-Desme S, Szathmari A, Carrie C (2008) Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol 10:599–607.  https://doi.org/10.1215/15228517-2008-029 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gokce-Samar Z, Beuriat PA, Faure-Conter C, Carrie C, Chabaud S, Claude L, di Rocco F, Mottolese C, Szathmari A, Chabert C, Frappaz D (2016) Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas. Childs Nerv Syst 32:1415–1423.  https://doi.org/10.1007/s00381-016-3153-8 CrossRefPubMedGoogle Scholar
  11. 11.
    Schwartzentruber J, Korshunov A, Liu X-Y et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature:1–8.  https://doi.org/10.1038/nature10833 CrossRefGoogle Scholar
  12. 12.
    Khuong-Quang D-A, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439–447.  https://doi.org/10.1007/s00401-012-0998-0 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J, Baker SJ, St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251–253.  https://doi.org/10.1038/ng.1102 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Merchant TE, Hua C-H, Shukla H et al (2008) Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 51:110–117.  https://doi.org/10.1002/pbc.21530 CrossRefPubMedGoogle Scholar
  15. 15.
    Fukushima H, Fukushima T, Suzuki R, Iwabuchi A, Hidaka K, Shinkai T, Masumoto K, Muroi A, Yamamoto T, Nakao T, Oshiro Y, Mizumoto M, Sakurai H, Sumazaki R (2017) Comorbidity and quality of life in childhood cancer survivors treated with proton beam therapy. Pediatr Int 59:1039–1045.  https://doi.org/10.1111/ped.13323 CrossRefPubMedGoogle Scholar
  16. 16.
    Mizumoto M, Murayama S, Akimoto T et al (2016) Proton beam therapy for pediatric malignancies: a retrospective observational multicenter study in Japan. Cancer Med 5:1519–1525.  https://doi.org/10.1002/cam4.743 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Navarria P (2019) Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). J Neurooncol 142:59–67.  https://doi.org/10.1007/s11060-018-03059-x CrossRefPubMedGoogle Scholar
  18. 18.
    Rao AD, Rashid AS, Chen Q et al (2017) Reirradiation for recurrent pediatric central nervous system malignancies: a multi-institutional review. Int J Radiat Oncol Biol Phys 99:634–641.  https://doi.org/10.1016/j.ijrobp.2017.07.026 CrossRefPubMedGoogle Scholar
  19. 19.
    Lu VM, Welby JP, Mahajan A, Laack NN, Daniels DJ (2019) Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis. Childs Nerv Syst 35:739–746.  https://doi.org/10.1007/s00381-019-04118-y CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  2. 2.Department of Radiation Oncology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  3. 3.Department of Pediatrics, Faculty of MedicineUniversity of TsukubaTsukubaJapan

Personalised recommendations